The purpose of this trial is to assess dose related safety, early efficacy, pharmacokinetics and pharmacodynamics of INT-787 in patients with severe alcohol-associated hepatitis (sAH).
1 Primary · 8 Secondary · Reporting Duration: Day 28, 56, 84
Active Control
Non-Treatment Group
50 Total Participants · 2 Treatment Groups
Primary Treatment: INT-787 · Has Placebo Group · Phase 2
Age 18 - 65 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: